Navigation Links
Caliper Life Sciences Ships 500th IVIS Imaging System
Date:1/31/2008

- Therapeutic Focus Drives Record Q4 Placement of IVIS Systems -

HOPKINTON, Mass., Jan. 31 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced the shipment of the 500th IVIS(R) molecular imaging system during the fourth quarter of 2007. Introduced in 2000, the IVIS molecular imaging system enables researchers to uniquely perform critical, noninvasive pre-clinical biological drug discovery and development research on small living mammals. The sale of the 500th IVIS system illustrates the growing demand for in vivo imaging to speed the drug discovery and development process without compromising accuracy and safety.

According to the Food and Drug Administration (FDA), while the number of investigational new drug (IND) applications has climbed throughout the last decade, the number of approved applications has declined. This underscores the increasing importance of early stage translational research efforts which are facilitated by IVIS systems. The molecular insight into living mammals that IVIS systems provide enables researchers to identify disease pathways, observe mechanisms of action and understand drug compound distribution and efficacy. Today, IVIS systems are widely utilized in the preclinical arena to create a bridge between in vitro and in vivo research and help researchers predict outcomes in humans.

"Caliper's IVIS systems continue to significantly impact the pharmaceutical industry's ability to bring new drugs to market, particularly in the area of cancer therapies," said Kevin Hrusovsky, CEO, Caliper Life Sciences. "We also see a sharp increase in the use of our IVIS imaging technology in therapeutic areas such as central nervous system (CNS), infectious and metabolic disease, and inflammation and we are continuing to expand our offerings to meet the demands of a broad market with specialized needs."

Caliper placed 51 IVIS systems during the fourth quarter of 2007 increasing the total IVIS installed base to 542 units and representing nearly $100 million of sales since the product's inception. Fourth quarter IVIS revenue growth was 42% as compared to the fourth quarter of 2006. The company estimates that approximately 25% of the IVIS units placed by its sales force in the fourth quarter will be used primarily in infectious disease research.

Caliper's IVIS offerings serve a broad array of therapeutic areas. In addition to the world's leading line of imaging instruments, Caliper also provides software, reagents, cell lines, animal models, application services and noninvasive imaging patent licenses to ensure that academic and commercial customers worldwide are able to quickly and effectively benefit from the company's technology.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of leading-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit http://www.caliperLS.com.

Caliper and IVIS are registered trademarks of Caliper Life Sciences, Inc.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Research and innovation at the intersection of physics and health sciences
2. Edwards Lifesciences Completes Sale of LifeStent Product Line to Bard
3. International Sports Sciences Associations Ten Best Resolutions for Better Health in 2008
4. Ardea Biosciences Lead NNRTI for HIV, RDEA806, to Enter Phase 2a Proof-of- Concept Clinical Trial
5. CDI-Life Sciences Selected by CJ CheilJedang Corp. to Provide Engineering Design for Major Pharmaceutical Complex in Korea
6. Derma Sciences Inc Selects Allen & Caron for Investor Relations and Corporate Communications
7. Advanced Life Sciences Completes Private Placement for $20 Million
8. Burrill & Company Reacquires Burrill Life Sciences Media Group LLC
9. SGI Introduces the SGI BioCluster Life Sciences Workflow Solution
10. Human Pheromone Sciences Announces Stock Repurchase Program
11. The Pittsburgh Life Sciences Greenhouse Announces New Chairman of the Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... , ... December 04, 2016 , ... ... major cosmetic surgery can now take advantage of a cosmetic procedure known as ... rejuvenation treatment that reduces the appearance of age spots, fine lines, uneven ...
(Date:12/4/2016)... ... December 04, 2016 , ... Responsible dental care hinges ... brush properly to achieve optimal results. This important necessity inspired an inventor from Las ... a way to ensure that people break or avoid bad techniques of brushing the ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in global ... Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New York ... who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and the ...
(Date:12/2/2016)... ... December 02, 2016 , ... On Dec. 2, 2016, CURE® magazine will host ... honoring the 2016 MPN Heroes—eight individuals who have made a difference in the field ... the standard of care, demonstrating leadership within the MPN community and/or a commitment to ...
(Date:12/2/2016)... Dothan, AL (PRWEB) , ... December 02, 2016 ... ... leaders from across the Dothan-Wiregrass Area in Alabama are expected to attend the ... Mike Schmitz, will help provide scholarship funds for area students and operating support ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... , Dec. 5, 2016 ... hydroxyurea (HU) in Complete Hematologic Response (CHR) ... ropeginterferon alfa-2b versus HU AOP will submit ... CONTINUATION-PV to obtain European marketing authorization in the coming months ... the FDA as it seeks approval for commercialization in the ...
(Date:12/4/2016)... 2016 Sickle cell disease (SCD) is an ... cells that get stuck in veins and block blood ... and complications leading to death. Each year, approximately 300,000 ... most of them lack access to comprehensive care or ... therapy for SCD, a pill called hydroxyurea approved more ...
(Date:12/2/2016)... SILVER SPRING, Md. , Dec. 2, 2016 /PRNewswire-USNewswire/ ... a new indication for Jardiance (empagliflozin) to reduce the ... 2 diabetes mellitus and cardiovascular disease. ... adults with type 2 diabetes mellitus," said Jean-Marc ... Metabolism and Endocrinology Products in FDA,s Center for Drug ...
Breaking Medicine Technology: